<i>HER2</i> Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

A. Perez, Edith; J. Suman, Vera; E. Davidson, Nancy; Martino, Silvana; A. Kaufman, Peter; L. Lingle, Wilma; J. Flynn, Patrick; N. Ingle, James; W. Visscher, Daniel; B. Jenkins, Robert

doi:10.1200/jco.2005.03.4744

Public

HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

Published in Journal of Clinical Oncology • Jun 30, 2006

Authors:

Edith A. Perez

Vera J. Suman

Nancy E. Davidson

Abstract

PURPOSE: To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab. PATIENTS AND METHODS: NCCTG N9831 is a randomized, phase III clinical trial comparing three drug regimens:...

Subject

Medicine

Concordance

Trastuzumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!